Evaluating the Risk of Irreversible Intestinal Necrosis Among Critically Ill Patients With Nonocclusive Mesenteric Ischemia

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Paul Calame ◽  
Hadrien Winiszewski ◽  
Alexandre Doussot ◽  
Alexandre Malakhia ◽  
Franck Grillet ◽  
...  
Author(s):  
Nicole C. Ruiz ◽  
Amir Y. Kamel ◽  
Bethany R. Shoulders ◽  
Martin D. Rosenthal ◽  
Irina M. Murray‐Casanova ◽  
...  

2018 ◽  
Vol 2018 ◽  
pp. 1-4
Author(s):  
Hideki Tanaka ◽  
Kiyoaki Tsukahara ◽  
Isaku Okamoto ◽  
Rio Kojima ◽  
Kazuhiro Hirasawa ◽  
...  

In nonocclusive mesenteric ischemia (NOMI), mesenteric ischemia and intestinal necrosis occur despite the absence of organic blockage in mesenteric blood vessels. As abdominal pain is often absent and few characteristic findings are seen in blood biochemistry, imaging diagnosis or other examinations, discovery is often delayed. With a mortality rate of 56–79%, NOMI is a very serious disease. However, few reports have described this pathology in association with chemotherapy regimens such as those used for malignant head and neck tumors. We encountered a case of NOMI during induction therapy combining cisplatin, docetaxel, and 5-fluorouracil. The patient was a 74-year-old man receiving chemotherapy for T2N2bM0 stage IVA oropharyngeal carcinoma. Febrile neutropenia appeared on treatment day 8. An antibacterial agent and a granulocyte colony-stimulating factor were administered, but septic shock developed and he was transferred to the intensive care unit. Abdominal distension was present and contrast-enhanced computed tomography of the abdomen suggested NOMI. Emergency surgery on day 9 resected the necrotized small intestine and created a single-hole ileostomy. The patient subsequently recovered with 2 weeks of continuous hemodiafiltration and other intensive therapies. Otolaryngological surgeons seldom encounter intestinal diseases, which are thus easily overlooked. The present case report may help in achieving early diagnosis.


2017 ◽  
Vol 2017 ◽  
pp. 1-7 ◽  
Author(s):  
Stefan Ludewig ◽  
Rami Jarbouh ◽  
Michael Ardelt ◽  
Henning Mothes ◽  
Falk Rauchfuß ◽  
...  

Background. Intestinal fatty acid-binding protein (I-FABP) has been shown to be of high diagnostic value in patients with acute mesenteric ischemia. Whether these results can be reproduced in critically ill patients on the ICU was to be investigated. Materials and Methods. I-FABP was measured in serum and urine of 43 critically ill patients in ICU when mesenteric ischemia was suspected. Bowel ischemia was confirmed in 21 patients (group 1). 22 patients who survived at least seven days without confirmation of ischemia were assigned to group 2. I-FABP levels were compared between the groups, and interval from the event that has triggered ischemia to I-FABP measurement was recorded. Results. For the identification of patients with mesenteric ischemia, sensitivity, specificity, and area under the curve (AUC) for serum and urine I-FABP were 33.3%, 95.5%, and 0.565 and 81.3%, 70.0%, and 0.694, respectively. I-FABP measurements performed within 12 to 48 h after the event that triggered ischemia showed a sensitivity, specificity, and AUC for serum and urine of 75%, 100%, and 0.853 and 100%, 73.3%, and 0.856, respectively. Conclusions. In ICU patients, one single I-FABP measurement at the time of clinical suspicion failed to reliably detect or exclude mesenteric ischemia. A higher diagnostic value of I-FABP was only confirmed in the early stages of mesenteric ischemia. I-FABP may be used most appropriately in perioperative monitoring.


2014 ◽  
Vol 77 (3) ◽  
pp. 441-447 ◽  
Author(s):  
Michael J. Lee ◽  
Jason L. Sperry ◽  
Matthew Randall Rosengart

Sign in / Sign up

Export Citation Format

Share Document